[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"ropivacaine\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:ropivacaine":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,53,83],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":31,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":42,"lastUpdatePostDateStruct":43,"startDateStruct":46,"completionDateStruct":47,"leadSponsor":49,"locationsCount":52},"100632144","liposomal-bupivacaine-versus-ropivacaine-with-perineural-dexamethasone-or-dexmedetomidine-as-adjuncts-for-adductor-canal-block-combined-with-ipack-block-in-total-knee-arthroplasty-100632144",false,"NCT07509866","Liposomal Bupivacaine Versus Ropivacaine With Perineural Dexamethasone or Dexmedetomidine as Adjuncts for Adductor Canal Block Combined With IPACK Block in Total Knee Arthroplasty","A Randomized Trial of Liposomal Bupivacaine, Ropivacaine With Perineural Dexamethasone, and Ropivacaine With Perineural Dexmedetomidine for Adductor Canal Block Combined With IPACK Block in Total Knee Arthroplasty","Inclusion Criteria:\n\n* Patients scheduled for elective primary unilateral total knee arthroplasty\n* Age ≥ 18 years and ≤ 80 years\n* American Society of Anesthesiologists (ASA) physical status I-III\n* Body mass index (BMI) ≥ 18 kg\u002Fm² and ≤ 35 kg\u002Fm²\n* Ability to understand and provide written informed consent\n\nExclusion Criteria:\n\n* Known allergy or contraindication to local anesthetics (bupivacaine, ropivacaine), dexamethasone, dexmedetomidine, or opioids\n* Infection at the injection site\n* Coagulopathy or current use of anticoagulants\n* Severe cardiovascular disease (New York Heart Association \\[NYHA\\] functional class III or IV, or recent myocardial infarction within 6 months)\n* Severe hepatic impairment (Child-Pugh class C) or renal impairment (estimated glomerular filtration rate \\[eGFR\\] \\\u003C 30 mL\u002Fmin\u002F1.73 m²)\n* Uncontrolled hypertension (systolic blood pressure \\> 180 mmHg or diastolic blood pressure \\> 110 mmHg despite medical therapy)\n* Uncontrolled diabetes mellitus (HbA1c \\> 8.5%)\n* Bilateral TKA or revision TKA\n* Chronic opioid use (daily opioid consumption for \\> 3 months prior to surgery)\n* Participation in another interventional clinical trial within 30 days prior to enrollment\n* Inability to communicate with study personnel or complete pain assessments (e.g., language barrier, cognitive impairment)","ALL","18 Years","80 Years",{"count":20,"type":21},90,"ESTIMATED","INTERVENTIONAL",[24],"NA","Effective postoperative pain management remains a cornerstone of enhanced recovery protocols following total knee arthroplasty (TKA). Inadequate analgesia not only compromises patient satisfaction but also impedes early mobilization and rehabilitation, thereby increasing the risk of perioperative complications. Current multimodal analgesic strategies frequently incorporate regional techniques, with the adductor canal block (ACB) and infiltration between the popliteal artery and capsule of the knee (IPACK) block emerging as established modalities that provide motor-sparing analgesia.\n\nDespite their widespread adoption, the optimal local anesthetic regimen for these blocks remains undefined. While liposomal bupivacaine has garnered interest for its extended duration of action, its clinical efficacy relative to conventional local anesthetics combined with perineural adjuncts remains a subject of ongoing debate. Specifically, perineural dexamethasone and dexmedetomidine have each demonstrated the capacity to prolong the analgesic duration of ropivacaine; however, direct comparative data among these three distinct strategies-liposomal bupivacaine alone versus ropivacaine supplemented with either adjunct-are notably limited.\n\nGiven the absence of head-to-head randomized trials evaluating these three clinically viable techniques, the optimal approach to maximize analgesic duration while minimizing opioid-related adverse effects remains unclear. This study therefore aims to compare the analgesic efficacy and safety profiles of liposomal bupivacaine, ropivacaine with perineural dexamethasone, and ropivacaine with perineural dexmedetomidine when administered via ACB and IPACK blocks in patients undergoing TKA.",[27,28,29,30],"Total Knee Anthroplasty","Nerve Block","Ropivacaine","Liposomal Bupivacaine",[32,33,34,35,36,37,38,39,40],"total knee arthroplasty","adductor canal block","IPACK block","liposomal bupivacaine","ropivacaine","perineural adjuncts","dexamethasone","dexmedetomidine","multimodal analgesia","RECRUITING","2026-04-09",{"date":44,"type":45},"2026-04-14","ACTUAL",{"date":42,"type":45},{"date":48,"type":21},"2026-12-30",{"name":50,"class":51},"Huazhong University of Science and Technology","OTHER",1,{"id":54,"slug":55,"hasResults":11,"nctId":56,"briefTitle":57,"officialTitle":58,"acronym":4,"eligibilityCriteria":59,"healthyVolunteers":11,"sex":60,"minAge":17,"maxAge":4,"enrollmentInfo":61,"targetDuration":4,"studyType":22,"phases":63,"briefSummary":64,"conditions":65,"keywords":69,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":75,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":52},"100593531","effects-of-ropivacaine-concentrations-on-prolonged-labor-analgesia-100593531","NCT07007650","Effects of Ropivacaine Concentrations on Prolonged Labor Analgesia","Effects of Different Concentrations of Ropivacaine on Prolonged Labor Analgesia","Inclusion Criteria:\n\n1. ASA II\n2. Age ≥ 18 years\n3. Singleton pregnancy\n4. No contraindications for epidural puncture and voluntarily accepting labor analgesia\n5. Maternal participants changing the first pump fluid\n\nExclusion Criteria:\n\n1. Contraindications for epidural labor analgesia\n2. Serious heart, brain, liver, or kidney diseases\n3. Mental abnormalities\n4. Neurological diseases\n5. Maternal request for management of breakthrough pain before changing the pump fluid","FEMALE",{"count":62,"type":21},100,[24],"With the changes in medical models and improvements in people's quality of life, parturients have higher demands for childbirth, making the alleviation and elimination of labor pain an important aspect of modern obstetrics. Intrathecal labor analgesia has been widely adopted in clinical practice to relieve pain. However, current studies mainly focus on parturients who are just beginning to receive labor analgesia, while for those experiencing prolonged analgesia, medical institutions still use traditional formulations, lacking relevant guidelines or expert consensus. In such cases, prolonged waiting and anxiety may lower the pain tolerance of parturients, leading to an increased need for higher concentrations of local anesthetics. To address this clinical gap, this study aims to explore the effects of different concentrations of ropivacaine in prolonged labor analgesia and has designed a prospective randomized controlled trial (RCT) to provide evidence for improving the analgesic regimen for this group of parturients.",[66,67,29,68],"Labor Analgesia","Prolonged","Concentration",[66,70,71,72],"Ropivacaine Concentration","Prolonged Pain","Maternal-Neonatal Safety","NOT_YET_RECRUITING","2025-06-05",{"date":76,"type":45},"2025-06-06",{"date":78,"type":21},"2025-06-14",{"date":80,"type":21},"2025-09-10",{"name":82,"class":51},"Chengdu Jinjiang Maternity and Child Health Hospital",{"id":84,"slug":85,"hasResults":11,"nctId":86,"briefTitle":87,"officialTitle":87,"acronym":88,"eligibilityCriteria":89,"healthyVolunteers":11,"sex":16,"minAge":90,"maxAge":18,"enrollmentInfo":91,"targetDuration":4,"studyType":22,"phases":93,"briefSummary":95,"conditions":96,"keywords":100,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":105,"lastUpdatePostDateStruct":106,"startDateStruct":108,"completionDateStruct":110,"leadSponsor":112,"locationsCount":114},"100502598","early-phase-1-testing-the-feasibility-of-using-ropivacaine-in-spinal-anesthesia-for-patients-with-lower-back-surgery-100502598","NCT05824338","Testing the Feasibility of Using Ropivacaine in Spinal Anesthesia for Patients With Lower Back Surgery","SASS","Inclusion Criteria:\n\n* Adult patients who are equal to or greater than 18 years old\n* Undergoing elective one or two-level lumbar surgery via posterior surgical approach in the prone position (between L2-S1)\n* Expected surgery duration of no greater than 2 hours\n* ASA Physical Status Class 1 to 3\n* Patient can have either spinal anesthesia or general anesthesia\n* Able to provide consent and understand information in English, and capable of answering questions in English\n\nExclusion Criteria:\n\n* Allergy to either ropivacaine, bupivacaine, or local anesthetics\n* Contraindications to spinal anesthesia (i.e. coagulopathy or on anticoagulants, severe aortic or mitral valve stenosis, sepsis or bacteremia, thrombocytopenia, high intracranial pressure, infection at the puncture site)\n* Surgery is expected to take more than 2 hours\n* Emergency surgery\n* Previously had back surgery at the level of the spine currently being operated on\n* Comorbidities that require the patient to undergo general anesthesia\n* Inability to stay still during the surgery\n* Inability to move legs preoperatively\n* Body Mass Index (BMI) \\>35\n* Multilevel severe spinal stenosis","19 Years",{"count":92,"type":21},45,[94],"EARLY_PHASE1","The goal of this pilot clinical trial is to test the feasibility of conducting a randomized controlled trial that will examine the use of ropivacaine in the spinal anesthesia for patients undergoing elective 1- or 2-level lower spine surgery. This study aims to:\n\n* Determine the rates of eligibility, recruitment, consent, and attrition\n* Determine the acceptability among patients, surgeons, anesthesiologists, and nurses of doing spine surgery under spinal anesthesia\n* Gather preliminary data on outcomes relevant to a future dose-finding study\n\nParticipants will be randomized to one of three treatment groups:\n\n* General anesthesia with endotracheal tube\n* Spinal anesthesia with bupivacaine\n* Spinal anesthesia with ropivacaine",[97,98,29,99],"Anesthesia, Spinal","Neurosurgery","Bupivacaine",[101,102,103,104],"Anesthesia","Spinal","Lumbar surgery","Lower back","2024-10-04",{"date":107,"type":45},"2024-10-08",{"date":109,"type":45},"2024-08-27",{"date":111,"type":21},"2025-12-31",{"name":113,"class":51},"Fraser Health",2]